Expiration Date: October 31, 2017
Media: Internet - based
Activity OverviewCommunity Practice Connections™: 17th Annual International Lung Cancer Congress® consists of a series of interactive clinical vignettes, short video interviews of leading lung cancer experts, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.
Instructions For This Activity & Receiving Credit
Target AudienceThis educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.
Learning ObjectivesAt the conclusion of this activity, participants should be better prepared to:
- Explain evolving approaches to characterize tumors using biomarkers and the methods by which testing can be facilitated in clinical practice for multiple lines of therapy
- Describe methods to personalize care in the management of thoracic malignancies based on clinical data sets, information that informs sequencing, performance status, and tumor characteristics
- Assess recent data and ongoing clinical trials evaluating single-agent and combination immuno-oncology strategies
- Place recent results from clinical trials in the context of evolving paradigms in the field of lung cancer and thoracic malignancies management
- Apply chemotherapeutic and molecularly targeted strategies to the management of advanced non–small cell lung cancer in multiple lines of therapy
- Identify appropriate patients to facilitate participation in clinical trials that are assessing emerging strategies to treat lung cancer
Disclosure Policy and Resolution of Conflicts of Interest (COI)As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI. Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multistep process.
Faculty, Staff, and Planners’ Disclosures
David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Disclosure: Grant/Research Support: AstraZeneca/Medi, Bristol Myers Squibb, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: Ariad, AstraZeneca, Boehringer Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Mirati, Novartis, Pfizer
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT
Disclosure: Grant/Research Support: Genentech, Merck; Consultant: Ariad, AstraZeneca, Lilly, Roche/Genentech, Merck, Pfizer; Other: Scientific Advisory Boards for Biothera, Diatech, Kolltan
Tony Mok, MD
Chinese University of Hong Kong
Hong Kong, China
Disclosure: Grant/Research Support: AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ, Roche, MSD, Clovis Oncology, Bristol Myers Squibb; Consultant: AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck Serono, MSD, Janssen, Clovis Oncology, BioMarin, GSK, Novartis, SFJ Pharmaceuticals, Vertex, ACEA Biosciences, Inc; Speaker’s Bureau: AstraZeneca, Roche/Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, MSD, Amgen, Janssen, Clovis Oncology, GSK, Novartis, Bristol Myers Squibb; Shareholder: Sanomics Limited
Suresh Ramalingam, MD
Chief of Thoracic Oncology
Director of Medical Oncology
Winship Cancer Institute of Emory University
Disclosure: Consultant: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Lilly, Genentech, Novartis.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
Requirements for Successful Completion
- You will need to login to participate in the activity.
- Please complete the demographic and pre-test questions.
- Each presentation may contain an interactive question(s). You may move forward through the presentations; however, you may not go back to change answers or review videos/content until you finish the presentation.
- At the end of the activity, "educational content/video" will be available for your reference.
In order to receive a CME/CE certificate, participants must:
- View the clinical data summaries and video commentaries
- Complete the posttest and pass with a score of 70% or higher
- Complete the evaluation, then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.